This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
Palvella Therapeutics has announced the issuance of a fifth patent for its lead product candidate, QTORIN™ rapamycin anhydrous gel, by the United States Patent and Trademark Office. This patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback